An experimental drug appears to reduce the risk of Alzheimer’s in people “destined” to develop the disease in middle age.
The study, published in the journal The Lancet Neurology, involved 73 people with rare, inherited genetic mutations that cause the overproduction of the protein amyloid in the brain. This all but guarantees they will develop Alzheimer's disease in their 30s, 40s or 50s.
